Globus Medical POLITICAL

Public-web evidence reviewed as of 21 October 2026. The scoped parent is Globus Medical, Inc., a Delaware corporation headquartered in Audubon, Pennsylvania. Its 2025 Form 10-K describes a musculoskeletal medical-device business focused on healthcare solutions and patient care.¹ Historical Israel evidence is treated separately from current operations, and neither commercial medical-device activity nor an Israeli corporate presence is treated as evidence of military procurement or deployment.

Corporate Communications & Public Stance

Statements. No public evidence identified in the bounded search of an official Globus Medical statement taking a position on the Israel-Palestine conflict, the Gaza war, Israeli military operations, Palestinian civilian harm, settlements or boycotts. The current corporate materials retrieved describe the company in healthcare and patient-care terms.^{1, 2, 3}

Comparative silence. Targeted searches for Globus statements concerning Gaza/Israel and, separately, Ukraine or Black Lives Matter did not produce enough attributable material to support a defensible comparative-silence finding. No public evidence identified.

Market framing. Globus’s 2023 and 2025 filings describe international activity as ordinary global medical-device sales conducted through direct personnel, independent representatives and distributors; the filings do not give Israel a special geopolitical characterization.^{1, 4}

Operations in Occupied or Contested Territories

Historical Israeli commercial presence. SEC subsidiary exhibits list Globus Medical Israel Ltd/Limited in 2012, 2014 and 2016 [pre-2020], and the entity was still listed in the subsidiary exhibit as of 31 December 2021.^{5, 6, 7, 8} A registry-mirror lead could not be independently retrieved, so its company-number, address and dissolution-date claims remain unresolved.

Dissolution/current status. Current legal status of the historical Israeli subsidiary remains unresolved. Globus’s 2025 Exhibit 21 does not list an Israeli subsidiary, while its current public office list likewise did not surface an Israel office in the material retrieved.^{9, 2} Exhibit 21 expressly omits subsidiaries that are not significant in the aggregate, so its omission is not conclusive proof that every form of Israeli commercial activity ceased.⁹

NuVasive and Nevro. NuVasive became a wholly owned Globus subsidiary on 1 September 2023.¹⁰ Nevro became a wholly owned Globus subsidiary on 3 April 2025.¹¹ Nevro’s pre-acquisition 2025 Exhibit 21 lists subsidiaries in Switzerland, the United Kingdom, Australia, Germany, Costa Rica and the United States, but no Israeli subsidiary.¹² Globus’s 2025 significant-subsidiary list includes NuVasive and Nevro entities but does not establish an Israeli entity for either acquired group.⁹

Civilian healthcare versus state or military activity. Globus describes its business as development and commercialization of musculoskeletal healthcare solutions, and its current regulatory materials identify Globus, NuVasive and related medical-device registrations.^{1, 3} The historical Israeli subsidiary therefore establishes an Israeli commercial nexus at the dates above; it does not establish an IDF customer, Ministry of Defense procurement, military deployment or combat use. No public evidence identified in this bounded search of Israeli military procurement or actual deployment.

Territorial presence and settlements. No public evidence identified establishing a Globus, NuVasive or Nevro office, branch, service site, distributor location, contract or equipment deployment in an Israeli settlement, the occupied West Bank, East Jerusalem or the occupied Golan Heights. The unverified registry-address lead is not used to establish territorial presence.

Legal/regulatory scrutiny. Exact-name searches directed at OHCHR settlement materials, Who Profits, AFSC Investigate and A/HRC/59/23 did not surface a substantive Globus-specific document within the bounded search. This is recorded as an unresolved negative result, not proof of non-inclusion.

Civil-society or boycott campaigns. No public evidence identified of a Globus Medical-specific organized BDS, divestment or sanctions campaign in the retrieved material.

Internal Governance, Content & Retail Policies

Employee relations. No public evidence identified of Globus, NuVasive or Nevro disciplining employees for pro-Palestinian speech, political symbols, Palestine-related union activity or similar conduct. The retrieved SEC governance materials identify ordinary corporate management and governance structures but did not surface such controversies.^{13, 14}

Platform/editorial policy. Globus’s disclosed business is medical technology rather than a consumer content or social-media platform.¹ no public evidence identified of Israel-Palestine-related algorithmic moderation, content suppression or editorial-policy scrutiny.

Retail and supply-chain practices. No public evidence identified of settlement-origin labeling disputes, settlement sourcing, region-specific product categorization or related regulatory action. The company’s current public regulatory material concerns medical-device registrations and accreditations.³

Brand Heritage & State Partnerships

Marketing positioning. Globus presents itself as a musculoskeletal healthcare and medical-technology company.¹ Founder and Executive Chairman David C. Paul’s published biography describes previous work at Synthes and Temple University biomaterials research, rather than a military or state-security origin.¹⁵ no public evidence identified of Globus marketing itself through Israeli military heritage or defense-sector origins.

Institutional ties and sponsorships. No public evidence identified of Globus accepting Israeli state honors, sponsoring a state-backed ‘Brand Israel’ campaign, or maintaining a non-commercial partnership with the Israeli government or military. The worker surfaced a possible Sheba Medical Center lead through the inaccessible registry mirror; without retrievable supporting evidence or a primary procurement record, it remains unresolved and is not treated as a contract.

Lobbying, Advocacy, Financing & Logistics

Political lobbying. No public evidence identified in the bounded search of Globus, NuVasive or Nevro lobbying on Israel-Palestine policy, anti-BDS legislation, settlement policy or Israel-related trade restrictions. Current proxy materials identify the company’s leadership and governance but did not surface such activity.¹³

Financial contributions. No public evidence identified of corporate donations or sponsorships by Globus, NuVasive or Nevro to the IDF, FIDF, JNF/KKL, Israeli reservist funds, settlement organizations, Regavim, Im Tirtzu or military-welfare bodies.

Crisis asset mobilization. No public evidence identified of Globus directing products, logistics, free medical services, infrastructure or other corporate assets to the Israeli military or a state-aligned conflict effort after 7 October 2023.

Corporate Structure & Primary Mission

Globus Medical, Inc. is a Delaware public company whose 2025 Form 10-K describes its mission as improving the quality of life of patients with musculoskeletal disorders.¹ Its disclosed business model centers on implants, enabling technologies and related medical products and services.^{1, 16} no public evidence identified of a charter mandate, state-held golden share or founding purpose tied to Israeli geopolitical objectives.

NuVasive became wholly owned by Globus in September 2023 and Nevro became wholly owned in April 2025, establishing the dates from which their corporate conduct is attributable to the Globus group for this audit.^{10, 11} Globus’s 2025 subsidiary exhibit lists NuVasive, LLC and Nevro, LLC among significant subsidiaries.⁹

Executive & Leadership Footprint

David C. Paul founded Globus and remains Chairman/Executive Chairman; the 2026 proxy identifies Keith W. Pfeil as President and Chief Executive Officer since July 2025.^{13, 15} [pre-2020] The 2017 proxy reported Paul holding 75.8% of combined voting power at that time.¹⁷ The 2024 proxy reported 66.3% voting power, confirming continued concentrated founder voting influence well after 2020.¹⁸

Personal philanthropy and financing. Targeted searches for David C. Paul and other leadership in connection with FIDF, JNF/KKL, settlement organizations, Israeli reservist funds and comparable entities produced no attributable substantive evidence. No public evidence identified.

Public advocacy and statements. No public evidence identified of David C. Paul, Keith W. Pfeil or the other retrieved senior leaders publishing Israel-Palestine op-eds, co-belligerency statements, anti-BDS advocacy or public endorsements of settlement activity.

Board memberships and affiliations. No public evidence identified of the retrieved controlling principals holding leadership roles in AIPAC, FIDF, JNF/KKL, CFI, anti-BDS organizations or settlement-advocacy groups. Paul’s official biography instead describes medical-device and academic engineering experience.¹⁵

Post-19 July 2024 / post-November 2024 conduct. The post-July 2024 corporate event established by the retrieved sources is the 2025 Nevro acquisition, a medical-device transaction with no stated Israel-Palestine purpose in the merger filing.¹¹ no public evidence identified in this bounded search of conflict-related political conduct by Globus or its controlling principals continuing or escalating after either reference date.